|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 11400 Rockville Pike |
Address2 |
|
| City | Rockville |
State | MD |
Zip Code | 20852 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104864-12
|
||||||||
|
6. House ID# 440290001
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Kelly Corredor |
Date | 10/13/2023 2:52:06 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ALC
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act.
Advocated for certain annual increases for Medicare office based SUD bundled codes.
ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models.
ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024.
ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications.
ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol.
ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications.
Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine.
Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths.
Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient.
Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment.
Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders.
Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder.
Advocated for continued telemedicine flexibilities related to medications for substance use disorder.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act.
Advocated for certain annual increases for Medicare office based SUD bundled codes.
ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models.
ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024.
ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications.
ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol.
ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications.
Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine.
Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths.
Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient.
Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment.
Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders.
Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder.
Advocated for continued telemedicine flexibilities related to medications for substance use disorder.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act.
Advocated for certain annual increases for Medicare office based SUD bundled codes.
ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models.
ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024.
ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications.
ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol.
ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications.
Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine.
Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths.
Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient.
Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment.
Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders.
Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder.
Advocated for continued telemedicine flexibilities related to medications for substance use disorder.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act.
Advocated for certain annual increases for Medicare office based SUD bundled codes.
ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models.
ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024.
ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications.
ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol.
ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications.
Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine.
Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths.
Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient.
Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment.
Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders.
Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder.
Advocated for continued telemedicine flexibilities related to medications for substance use disorder.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act.
Advocated for certain annual increases for Medicare office based SUD bundled codes.
ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models.
ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024.
ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications.
ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol.
ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications.
Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine.
Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths.
Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient.
Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment.
Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders.
Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder.
Advocated for continued telemedicine flexibilities related to medications for substance use disorder.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
Advocated for increased FY24 funding for HRSA's Addiction Medicine Fellowship Program ($30M)
Advocated for increased FY24 funding for HRSA's Substance Use Disorder Treatment and Recovery Loan Repayment Program ($50M)
Advocated for (S. 644/H.R. 1359) the Modernizing Opioid Treatment Access Act, which would allow specially registered opioid treatment program clinicians and addiction specialist physicians to prescribe methadone for OUD that can be picked up from pharmacies, subject to federal regulation or guidance on supply of methadone for unsupervised use.
Advocated for S. 1165/ HR 2400- the Reentry Act, which would allow states to provide Medicaid coverage to eligible individuals up to 30 days prior to release from incarceration
Advocated for HR 3074/S.971 - Due Process Continuity of Care Act, which would amend title XIX of the Social Security Act to remove the Medicaid coverage exclusion for inmates in custody pending disposition of charges, and for other purposes.
Worked on draft legislation that would provide Medicare coverage for evidence-based residential SUD services
Supported H.R.1502 - Comprehensive Opioid Recovery Centers Reauthorization Act of 2023, in its entirety
Advocated for removal of in-person evaluation requirement in proposed telemedicine rules by the DEA and worked on related draft legislation
Opposed proposed changes to the STAR-LRP program in S.462 - the Mental Health Professionals Workforce Shortage Loan Repayment Act of 2023
Advocated for removal of a lifetime ban that prevents individuals convicted of a drug felony from receiving Supplemental Nutritional Assistance Program (SNAP) or Temporary Assistance for Needy Families TANF) as part of the next Farm Bill.
Advocated for various substance use disorder workforce and coverage policy changes, including some of which appear in H.R. 4531, the Support for Patients and Communities Reauthorization Act.
Advocated for certain annual increases for Medicare office based SUD bundled codes.
ASAM signed a letter in support of S. 1378, Connecting Our Medical Providers with Links to Expand Tailored and Effective Act (the "COMPLETE Act"), which would advance collaborative care models.
ASAM signed a letter sent by a broad coalition of health care clinicians, patient advocates, and other stakeholders, urging Congressional leaders to support the Centers for Medicare and Medicaid Services' (CMS) proposal to implement a Medicare billing code, known as G2211, in 2024.
ASAM submitted comments to the Centers for Medicare and Medicaid Services (CMS) on the proposed 2024 MPFS and OPPS rules, encouraging CMS to finalize many new Medicare proposals, with several modifications.
ASAM joined several other organizations in a letter to the leadership of the House Committee on Oversight and Accountability opposing the U.S. Shipping Equity Act (H.R. 3721) that would allow the U.S. Post Office (USPS) to ship beverage alcohol.
ASAM signed a letter supporting the Helping Tobacco Users Quit Act (H.R. 4775), which would ensure Medicaid and Childrens Health Insurance Program (CHIP) enrollees have access to all evidence-based tobacco cessation treatments, including seven Food and Drug Administration-approved medications.
Advocated for DEA related clarifications or changes to registration requirements related to the delivery of injectable buprenorphine.
Supported S 2919 - Advancing Lifesaving Efforts with Rapid Test Strips for Communities Act (ALERT Communities Act) to help expand access to fentanyl and xylazine test strips, a critical tool to help lower overdose deaths.
Supported HR 5506 - Hospitals As Naloxone Distribution Sites (HANDS) Act, which would require Medicare, Medicaid, and TRICARE to cover the cost when medical providers physically hand naloxone to patients who are at risk of an overdose, before they are discharged, at zero cost to the patient.
Supported H.R.5163 - Telehealth Response for E-prescribing Addiction Therapy Services Act, which would amend the Controlled Substances Act to allow for the use of telehealth in substance use disorder treatment.
Supported S.3006 - SAFE in Recovery Act, which would ensure comprehensive wraparound services for families impacted by substance use disorders.
Advocated for reforms to the Child Abuse Prevention and Treatment Act related to pregnant women who take medications for substance use disorder.
Advocated for continued telemedicine flexibilities related to medications for substance use disorder.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Natl Drug Control Policy (NDCP), Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Congressional Budget Office (CBO), Health Resources & Services Administration (HRSA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Kelly |
Corredor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |